eptinezumab-jjmr (Vyepti)
eptinezumab-jjmr is an FDA-licensed reference biologic from Lundbeck Seattle BioPharmaceuticals, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2020
Reference approved
Reference product
Vyepti eptinezumab-jjmr
Lundbeck Seattle BioPharmaceuticals, Inc.
- Approved
- Feb 21, 2020
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for eptinezumab-jjmr, in chronological order.
Reference approval
Approval date of the reference eptinezumab-jjmr product.
6 yr 4 mo ago
Frequently asked questions
Are there biosimilars approved for eptinezumab-jjmr (Vyepti)?
No 351(k) biosimilars or interchangeable biosimilars referencing eptinezumab-jjmr are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.